Share on StockTwits

Auxilium Pharmaceuticals (NASDAQ:AUXL) released its earnings data on Thursday. The company reported ($0.44) EPS for the quarter, missing the Thomson Reuters consensus estimate of $1.64 by $2.08, Analyst Ratings Net reports. The company had revenue of $83.00 million for the quarter, compared to the consensus estimate of $482.80 million.

A number of research firms have recently commented on AUXL. Analysts at Aegis initiated coverage on shares of Auxilium Pharmaceuticals in a research note on Thursday, June 26th. They set a “buy” rating and a $37.00 price target on the stock. On a related note, analysts at MKM Partners upgraded shares of Auxilium Pharmaceuticals from a “neutral” rating to a “buy” rating in a research note on Wednesday, May 28th. They now have a $26.00 price target on the stock. They noted that the move was a valuation call. Finally, analysts at TheStreet downgraded shares of Auxilium Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Thursday, May 22nd. Four analysts have rated the stock with a sell rating, two have assigned a hold rating and nine have assigned a buy rating to the company’s stock. Auxilium Pharmaceuticals presently has a consensus rating of “Hold” and an average target price of $26.79.

Auxilium Pharmaceuticals (NASDAQ:AUXL) opened at 19.834 on Thursday. Auxilium Pharmaceuticals has a 52-week low of $16.36 and a 52-week high of $32.89. The stock’s 50-day moving average is $20.09 and its 200-day moving average is $23.99. The company’s market cap is $996.3 million.

Auxilium Pharmaceuticals, Inc is a specialty biopharmaceutical company focuses on developing and marketing products to predominantly specialist audiences.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.